Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/dia.2005.7.230 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transdermal reverse iontophoresis: A novel technique for therapeutic drug monitoring.
J Control Release
January 2017
NSHM College of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata Group of Institutions, 124 BL Saha Road, Kolkata-700053, West Bengal, India. Electronic address:
Application of transdermal reverse iontophoresis for diagnostic purpose is a relatively new concept but its short span of research is full of ups and downs. In early nineties, when the idea was floated, it received a dubious welcome by the scientific community. Yet to the disbelief of many, 2001 saw the launching of GlucoWatch® G2 Biographer, the first device that could measure the blood sugar level noninvasively.
View Article and Find Full Text PDFRandomized controlled trial to assess the impact of continuous glucose monitoring on HbA(1c) in insulin-treated diabetes (MITRE Study).
Diabet Med
May 2009
Department of Epidemiology and Public Health, University College London, Gower Street Campus, 1-19 Torrington Place, London, UK.
Aims: To determine whether continuous glucose information provided through use of either the GlucoWatch G2 Biographer or the MiniMed continuous glucose monitoring system (CGMS) results in improved glycated haemoglobin (HbA(1c)) for insulin-treated adults with diabetes mellitus, relative to an attention control and standard care group.
Methods: Four hundred and four adults taking at least two daily insulin injections and with two consecutive HbA(1c) values > or = 7.5% were recruited to this randomized controlled trial (RCT).
The chemistry of commercial continuous glucose monitors.
Diabetes Technol Ther
June 2009
Abbott Diabetes Care, Alameda, California 94502, USA.
The analytical methodologies of the continuous glucose monitors (CGMs) commercialized to date are described. The devices include two noninvasive products: the GlucoWatch (Cygnus, Redwood City, CA) G2 Biographer uses iontophoresis to obtain a sample and electrochemistry for glucose detection, and PENDRA (Pendragon Medical Ltd., Zurich, Switzerland) utilizes impedance spectroscopy.
View Article and Find Full Text PDFObjectives: To evaluate whether the additional information provided by minimally invasive glucose monitors results in improved glycaemic control in people with poorly controlled insulin-requiring diabetes, and to assess the acceptability and health economic impact of the devices.
Design: A four-arm randomised controlled trial was undertaken.
Setting: Participants were recruited from secondary care diabetes clinics in four hospitals in England.
Development and piloting of an acceptability questionnaire for continuous glucose monitoring devices.
Diabetes Technol Ther
April 2008
Centre for Behavioural & Social Sciences in Medicine, University College London, United Kingdom.
Background: User acceptability of new health technologies is important in determining their widespread use and adoption. The aim of this current study was twofold: first, to investigate the acceptability of two continuous glucose monitoring devices for people with diabetes; and second, to develop a valid questionnaire measure to assess the acceptability of continuous glucose monitoring devices.
Methods: Semi-structured interviews were conducted with six people with diabetes who had previously used the GlucoWatchBiographer (Animas Corp.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!